In the completed phase I and II trials in ALS patients ( ClinicalTrials.gov Identifier: NCT01091142 , NCT01281631 ), NP001 was found to be safe, well tolerated, and presented a positive trend in slowing disease progression ( 120 , 121 ).
← all excerpts
Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications.
1
—
—